Preoperative systemic immune‐inflammation index as a significant prognostic factor after TURBT in patients with non‐muscle‐invasive bladder cancer: A retrospective study based on propensity score matching analysis

Abstract

Objective To investigate the association of the preoperative systemic immune‐inflammation index (SII) with recurrence‐free survival (RFS) after transurethral resection of the bladder tumor (TURBT) of non‐muscle‐invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. Methods The clinicopathological characteristics and follow‐up data of NMIBC patients were collected retrospectively from two tertiary medical centers. A 1:1 PSM analysis was carried out using the nearest‐neighbor method (caliper size: 0.02). Cox regression analysis was used to identify the risk factors associated with RFS. Results A total of 416 NMIBC patients were included in this study. Before and after matching, patients with increased SII had worse RFS ( p < 0.0001 and p = 0.027, respectively). Multivariate Cox analysis identified SII as an independent predictor of RFS before (HR [95% CI]: 1.789 [1.232, 2.599], p = 0.002) and after matching (HR [95% CI]: 1.646 [1.077, 2.515], p = 0.021). In the matched subgroup analysis, an elevated SII had a significant association with postoperative worse RFS in the T1 stage ( p = 0.025), primary status ( p = 0.049), high‐grade ( p = 0.0015), and multiple lesions ( p = 0.043) subgroups. Conclusion SII could accurately stratify the prognosis of NMIBC patients before and after PSM analysis. An elevated SII was significantly associated with worse RFS in NMIBC patients.

Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma

“…11 studies (involving 12 datasets) comprising 10577 patients reported on the prognostic effect of preoperative SII on RFS in UC patients ( 11 , 13 , 18 , 19 , 23 , 24 , 26 , 27 , 29 , 30 , 32 ). The pooled analysis demonstrated that higher preoperative SII in UC patients was an independent predictor of RFS (HR = 1.240, 95% CI 1.097-1.403, p=0.001), with significant heterogeneity (I 2 = 78.0%, p<0.001) ( Figure 4 , Table 2 ).…”

“…After having read the titles and abstracts, 35 potentially eligible papers underwent full-text reviewing. Finally, 19 studies that comprised 12505 patients were included in this meta-analysis (11,(13)(14)(15)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32). All the included studies have been published within the last 5 years (2019-2023); 13 studies focused on BC, 5 studies about UTUC, and the last one was on mixed (BC and 1.…”

Preoperative Systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma

“…Finally, 19 studies that comprised 12505 patients were included in this meta-analysis [10,[12][13][14][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. All the included studies have been published within the last 5 years (2019-2023); 13 studies focused on BC, 5 studies about UTUC, and the last one on mixed(BC and UTUC).…”

“…Prognostic signi cance of SII on RFS in patients With UC 11 studies (involving 12 datasets) comprising 10577 patients reported on the prognostic effect of preoperative SII on RFS in UC patients [10,12,17,18,22,23,25,26,28,29,31]. The pooled analysis demonstrated that higher preoperative SII in UC patients was an independent predictor of RFS (HR = 1.240, 95% CI 1.097-1.403, p = 0.001), with signi cant heterogeneity (I 2 = 78.0%, p < 0.001) (Fig.…”

The association of systemic immune-inflammation index with lung function, risk of COPD and COPD severity: A population-based study

“…As in many previous studies, the SII is an important tool for predicting the prognosis and survival rate of patients with malignant tumors, spontaneous cerebral hemorrhage, and cerebral infarction. This index could provide an accurate assessment of a patient's inflammatory and immune status, allowing clinicians to gain a better understanding of the patient's condition and develop an appropriate treatment plan [7][8][9][10][11].…”